Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA.

Authors

Thomas Gruenberger

Medical University Hospital, Vienna, Austria

Thomas Gruenberger , John A. Bridgewater , Ian Chau , Pilar Garcia Alfonso , Michel Rivoire , Susan Lasserre , Daniel Waterkamp , Rene Adam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

FOLFOXIRI with or without bevacizumab as first-line treatment for unresectable liver-only metastatic colorectal cancer patients with RAS mutation-type.

First Author: Yanhong Deng

insert_chart_outlined

Poster

2022 ASCO Gastrointestinal Cancers Symposium

bookmark_border

A multicenter phase II trial to assess the efficacy and safety of bevacizumab plus mFOLFOX6 as induction chemotherapy toward R0 surgical resection in advanced colorectal liver metastases with mutant-type KRAS: NEXTO-mt trial.

First Author: Genki Watanabe

insert_chart_outlined

Poster

2021 Gastrointestinal Cancers Symposium

bookmark_border

Conversion from unresectable to resectable liver metastases in real-world patients with liver-only metastatic colorectal cancer (mCRC) treated with FOLFOXIRI plus bevacizumab: The Conversion trial.

First Author: Shahid Ahmed

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

REsect: Blinded assessment of amenability to potentially curative treatment of previously unresectable colorectal cancer liver metastases (CRC LM) after chemotherapy ± RadioEmbolization (SIRT) in the randomized SIRFLOX trial.

First Author: Benjamin Garlipp